



## SmartLIO™

### Advanced Laser Indirect Ophthalmoscope\*

The new Smart LIO™ is a wireless multi-color Laser Indirect Ophthalmoscope (LIO) that supports three wavelengths (green, yellow and red).

Smart LIO™ offers the most advanced LED illumination technology, providing brighter, whiter illumination, longer battery life, and LED life expectancy of up to 10,000 hours.

\* Pending US market clearance

## LumeProbe™

### Ophthalmic Endo-Ocular Probes

The LumeProbe™ product family was designed to deliver laser energy safely and efficiently, guaranteeing optimal clinical outcomes for all relevant vitreoretinal indications.

**Gauge:** 20, 23, 25.

**Types:** Straight, Curved and Aspirating (multifunctional)

Manufactured by Lumenis Inc.  
1870 South Milestone Drive  
Salt Lake City, UT 84104 USA  
Tel +801-656-2300  
Fax +801-656-2429

Lumenis (Germany) GmbH  
Heinrich-Hertz-Str 3 D-63303  
Dreieich-Dreieichenhain  
GERMANY  
Tel +49 (0) 6103 8335 0

**AMERICAS**  
San Jose, CA, USA  
Tel +1 408 764 3000  
+1 877 586 3647  
Fax +1 408 764 3999

**EMEA**  
Dreieich Dreieichenhain,  
Germany  
Tel +49 6103 8335 0  
Fax +49 6103 8335 300  
Roma (RM), Italy  
Tel +39 06 90 75 230  
Fax +39 06 90 75 269  
Hertfordshire, UK  
Tel +44 20 8736 4110  
Fax +44 20 8736 4119

**JAPAN**  
Tokyo, Japan  
Tel +81 3 4431 8300  
Fax +81 3 4431 8301

**ASIA / PACIFIC**  
Beijing, China  
Tel +86 10 5737 6677  
Gurgaon, India  
Tel +91 124 422 07 95  
Kowloon, Hong Kong  
Tel +852 217 428 00  
Fax +852 272 251 51

[www.lumenis.com/Ophthalmology](http://www.lumenis.com/Ophthalmology)

Lumenis® Certified Service | USA Toll-free 1-877-LUMENIS (1-877-586-3647)

© 2017 All Rights Reserved. The Lumenis Group of Companies. PB-2007098 Rev B

**Lumenis®**  
Energy to Eye Care


## Lumenis Retina

### Lumenis Proudly Launches its New Retinal Care Portfolio



**Lumenis®**  
Energy to Eye Care





1970: Lumenis (previously Coherent) introduces the first argon laser photocoagulator in ophthalmology.

2016: Lumenis proudly launches the new retinal care portfolio, starring the Smart 532™, green photocoagulator with SmartPulse™.




# Smart532

## The SmartPulse™ of Retinal Care

Smart 532™ is the newest photocoagulator by Lumenis, enhanced with the advanced SmartPulse™ technology.

- Continuous wave and SmartPulse™ sub-threshold technology
- Superior laser stability due to advanced laser cavity technology
- 100% Lumenis Technology
- Exclusive and intuitive user interface
- Compact and lightweight
- Dual port designed to best fit the clinic
- 25 programmable user pre-sets
- SureSpot™ optics technology ensures sharply defined power on the retina with safe and low density power on the cornea
- Voice confirmation mode enables the physician to keep eyes on the patient while changing settings during treatment

### SmartPulse™ Mode



# Array LaserLink™

## Pattern Scanning Laser Technology

The Array™ LaserLink™ offers advanced pattern scanning capabilities compatible with all Lumenis laser systems and popular slit lamps, wavelength versatility, diverse adjustable patterns and a wide range of laser spot sizes.

Pattern scanning laser provides enhanced laser application uniformity, shortens treatment time, and offers more patient comfort.



# Vision One

## One System Three Wavelengths

Cleverly designed multi-wavelength photocoagulator with green (532nm), yellow (577nm) and red (659nm) wavelengths. A fully customized solution, allowing the physician to choose one, two, or three independent laser cavities, with the ability to upgrade the system at any time.

Lumenis is the pioneer of multi-wavelength photocoagulation technology (1983) and one of the global leaders in multi-color ophthalmic lasers.

**Risks and warnings:** Lumenis photocoagulators and delivery devices are intended solely for use by trained physicians. It is contraindicated for eyes with severe media opacities. Risks include increased macular edema and bleeding in areas of neovascularization. Refer to the operator manual for a complete list of intended use, contraindications and risks.